PR88402

AMERSHAM, United Kingdom, March 9, 2021 /PRNewswire=KYODO JBN/ --

- A survey of 1,165 biopharma executives and healthcare policymakers across 20

countries measured ability of industry to respond to global needs in five

areas: Supply chain resilience, talent pool, R&D ecosystem, manufacturing

agility, and government policy and regulation

- There is a strong correlation between higher performing countries and higher

income per capita; United States leads the index overall but Switzerland and

China have most resilient supply chains

- First such study to cover wide range of topics and respondents

Global life sciences leader Cytiva, along with the Financial Times' research

arm Longitude, have compiled a global index, ranking the ability of the

biopharma industry to respond to five major challenges; in supply chain,

talent, research and development, manufacturing, and government policy and

regulation.

Respondents answered questions on a scale of 1 to 10 in each of the five

areas.  The average of all responses resulted in the rating of each country's

biopharma capabilities as well as the strength of the global industry. With an

overall index score of 6.6 out of 10, the industry looks vulnerable - and has

scope to improve across a number of critical areas. In the overall index, the

United States ranks first, with a 7.12 score. Switzerland and the UK follow

closely.

Russia, China and India are leading in the lower-middle income and

upper-middle-income economy countries(1), despite having large populations and

lower GNI per capita than some of the other countries in this group. However,

the index also highlights a clear divide between high-income vs

upper-middle-income and lower-middle-income economies. The upper-middle-income

and lower-middle-income economies tend to score lower on the index: this

indicates that they have less resilient biopharma industries, which creates a

significant risk in terms of global access to vital medications.

Emmanuel Ligner, President and CEO, Cytiva, says: "As a partner to global

biopharma companies, we wanted to offer this overview of where the industry is

performing well, and where there are some pain points.  The data is built by

listening to customers and key players, and gives us insight into major

concerns. With this data, we'll have even more fruitful conversations and be

better prepared to work with customers and stakeholders to address

industry-wide challenges."

Kiran Mazumdar-Shaw, founder and chairperson of Biocon, says: "Biopharma has a

huge role to play in the future of medicine, and many of the medicines that we

are developing now will be game-changing. But developing blockbuster drugs

shouldn't be about making a billion dollars - it should be about serving a

billion patients. That's when we will have global equity in healthcare."

The index was built from 1,165 survey respondents across 20 countries (95%

pharma and biopharma executives and 5% healthcare policymakers), in addition to

in-depth interviews with eight experts from biopharma and healthcare

policymaking.

For the full report and more facts, visit this page (

https://c212.net/c/link/?t=0&l=en&o=3089997-1&h=1271337324&u=https%3A%2F%2Fwww.ft.com%2Fpartnercontent%2Fcytiva%2Fhub.html&a=this+page

).

About Cytiva

Cytiva is a global life sciences leader with more than 7,000 associates across

40 countries dedicated to advancing and accelerating therapeutics. As a trusted

partner to customers that range in scale and scope, Cytiva brings speed,

efficiency and capacity to research and manufacturing workflows, enabling the

development, manufacture and delivery of transformative medicines to patients.

(1) Using the World Bank country classifications, based on gross national

income per capita

SOURCE  Cytiva

CONTACT: US/Europe, Colleen Connolly, Colleen.connolly@cytiva.com, or Asia

Pacific, Iris Zhao, Meng.zhao@cytiva.com